Joel Oger

Joel Oger

UNVERIFIED PROFILE

Are you Joel Oger?   Register this Author

Register author
Joel Oger

Joel Oger

Publications by authors named "Joel Oger"

Are you Joel Oger?   Register this Author

74Publications

1040Reads

37Profile Views

Multiple sclerosis: effect of beta interferon treatment on survival.

Brain 2019 May;142(5):1324-1333

Faculty of Medicine (Neurology) and the Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/brain/awz055DOI Listing
May 2019

Disability progression in aggressive multiple sclerosis.

Mult Scler 2017 Mar 11;23(3):456-463. Epub 2016 Jul 11.

Division of Neurology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458516653273DOI Listing
March 2017

Association between the use of selective serotonin reuptake inhibitors and multiple sclerosis disability progression.

Pharmacoepidemiol Drug Saf 2016 10 23;25(10):1150-1159. Epub 2016 May 23.

Department of Medicine, Division of Neurology and Centre for Brain Health, University of British Columbia, Vancouver, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pds.4031DOI Listing
October 2016

Randomized Trial of Thymectomy in Myasthenia Gravis.

N Engl J Med 2016 08;375(6):511-22

From the Department of Neurology, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo (G.I.W.), the Department of Neurology, University of Rochester Medical Center, Rochester (E.C.), and the Section of General Thoracic Surgery, Columbia University Medical Center, New York (J.R.S., A.J.) - all in New York; the Department of Neurology, George Washington University School of Medicine and Health Sciences, Washington, DC (H.J.K.); the Department of Biostatistics, University of Alabama at Birmingham, Birmingham (I.B.A., G.M., H.-C.K., G.R.C.); the Institute of Pathology, University Medical Center Mannheim, University of Heidelberg, Mannheim (A.M.), the Institute of Pathology, University of Göttingen, Göttingen (P.S.), and the Department of Neurology, Johannes Gutenberg University, Mainz (W.N.) - all in Germany; the Department of Neurology, University of Buenos Aires, Buenos Aires (C.M.); the Division of Neurology, University of British Columbia, Vancouver (J. Oger), and the Department of Neurology, McGill University, Montreal (C.H.C.) - both in Canada; the Department of Neurology, University of Chile, Santiago (J.G.C.); the Division of Neurology, Department of Medicine, University of Cape Town, Cape Town, South Africa (J.M.H.); the Department of Neurology, Catholic University (A.E.), and the Department of Neurosciences, Mental Health and Sensory Organs, Sapienza University of Rome (G.A.) - both in Rome; the Division of Neurology, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (R.W.); the Department of Neurology, University of Melbourne, Melbourne, VIC, Australia (J.O.K.); the Department of Neurology, University of Southern California, Los Angeles (S.R.B.), and the Department of Neurology, University of California Irvine Medical Center, Orange (T.M.) - both in California; the Department of Neurology, Medical College of Wisconsin, Milwaukee (A.C.B.); the Department of Neurology, Harvard Medical School, Boston (A.A.A.); Nerve and M

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1602489DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5189669PMC
August 2016

Multiple sclerosis in older adults: the clinical profile and impact of interferon Beta treatment.

Biomed Res Int 2015 1;2015:451912. Epub 2015 Apr 1.

Department of Medicine, Division of Neurology and Brain Research Centre, UBC Hospital, University of British Columbia, 2211 Wesbrook Mall, Vancouver, BC, Canada V6T 2B5.

View Article

Download full-text PDF

Source
http://downloads.hindawi.com/journals/bmri/2015/451912.pdf
Web Search
http://www.hindawi.com/journals/bmri/2015/451912/
Publisher Site
http://dx.doi.org/10.1155/2015/451912DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397470PMC
February 2016

A longitudinal model for disease progression was developed and applied to multiple sclerosis.

J Clin Epidemiol 2015 Nov 14;68(11):1355-65. Epub 2015 May 14.

School of Social and Community Medicine, University of Bristol, Canynge Hall, 39 Whatley Road, BS8 2PS, UK.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S08954356150022
Publisher Site
http://dx.doi.org/10.1016/j.jclinepi.2015.05.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643305PMC
November 2015

Amyotrophic lateral sclerosis presentation of a human T-lymphotropic virus type-1 myelopathy--insight into pathogenesis.

APMIS 2015 Sep 30;123(9):815-20. Epub 2015 Jul 30.

Division of Neurology, Department of Medicine and Brain Research Centre, UBC Hospital, University of British Columbia, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apm.12422DOI Listing
September 2015

An update on laboratory diagnosis in myasthenia gravis.

Clin Chim Acta 2015 Sep 1;449:43-8. Epub 2015 Aug 1.

Division of Neurology, Department of Medicine, UBC Vancouver, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cca.2015.07.030DOI Listing
September 2015

Treatment of Myasthenia Gravis in the Aged.

Drugs Aging 2015 Sep;32(9):689-97

Division of Neurology, Department of Medicine and Brain Research Centre, UBC Hospital, University of British Columbia, 2211 Wesbrook Mall, Vancouver, V6T 2B5, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40266-015-0297-2DOI Listing
September 2015

A genome-wide association study of myasthenia gravis.

JAMA Neurol 2015 Apr;72(4):396-404

Neuromuscular Diseases Research Unit, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Porter Neuroscience Research Center, Bethesda, Maryland11Department of Neurology, Johns Hopkins School of Medicine, Baltimore, M.

View Article

Download full-text PDF

Source
http://www.viverelamiastenia.it/file/JAMA%20Neurology_MG%20G
Web Search
http://archneur.jamanetwork.com/article.aspx?doi=10.1001/jam
Publisher Site
http://dx.doi.org/10.1001/jamaneurol.2014.4103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856525PMC
April 2015

An update on laboratory diagnosis in myasthenia gravis.

Clin Chim Acta 2015 Apr 15;444:126-31. Epub 2015 Feb 15.

Division of Neurology, Department of Medicine, UBC Vancouver, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cca.2015.01.042DOI Listing
April 2015

Serum proteomics in multiple sclerosis disease progression.

J Proteomics 2015 Apr 6;118:2-11. Epub 2015 Mar 6.

PROOF Centre of Excellence, Vancouver, BC V6Z 1Y6, Canada; Department of Statistics, University of British Columbia, Vancouver, BC V6T 1Z4, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jprot.2015.02.018DOI Listing
April 2015

Antibody dissociation rates are predictive of neutralizing antibody (NAb) course: a comparison of interferon beta-1b-treated Multiple Sclerosis (MS) patients with transient versus sustained NAbs.

Clin Immunol 2015 Mar 24;157(1):91-101. Epub 2014 Dec 24.

NeuroImmunology Laboratories, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clim.2014.12.005DOI Listing
March 2015

Association between beta-interferon exposure and hospital events in multiple sclerosis.

Pharmacoepidemiol Drug Saf 2014 Nov 21;23(11):1213-22. Epub 2014 Jun 21.

College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pds.3667DOI Listing
November 2014

Assessment of cancer risk with β-interferon treatment for multiple sclerosis.

J Neurol Neurosurg Psychiatry 2014 Oct 4;85(10):1096-102. Epub 2014 Mar 4.

Faculty of Medicine Division of Neurology, Multiple Sclerosis Program University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jnnp-2013-307238DOI Listing
October 2014

Short-term and long-term safety and tolerability of interferon β-1b in multiple sclerosis.

Mult Scler Relat Disord 2014 May 26;3(3):294-302. Epub 2013 Nov 26.

Bayer HealthCare Pharmaceuticals, 100 Bayer Boulevard, Whippany 07981, NJ, United States. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S22110348130013
Publisher Site
http://dx.doi.org/10.1016/j.msard.2013.11.005DOI Listing
May 2014

Characterising aggressive multiple sclerosis.

J Neurol Neurosurg Psychiatry 2013 Nov 6;84(11):1192-8. Epub 2013 Jun 6.

Department of Medicine, Division of Neurology, University of British Columbia, , Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jnnp-2013-304951DOI Listing
November 2013

Late-onset myasthenia gravis: a review when incidence in older adults keeps increasing.

Muscle Nerve 2013 Nov;48(5):705-10

Division of Neurology, Department of Medicine and Brain Research Centre, UBC Hospital, University of British Columbia, 2211 Westbrook Mall, Vancouver, British Columbia, V6T 2B5, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mus.23964DOI Listing
November 2013

Somatostatin preserved blood brain barrier against cytokine induced alterations: possible role in multiple sclerosis.

Biochem Pharmacol 2013 Aug 13;86(4):497-507. Epub 2013 Jun 13.

Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2013.06.001DOI Listing
August 2013

DMDs are an essential issue but are they the only issue in MS treatment?

Can J Neurol Sci 2013 May;40(3):276-7

UBC Hosptial, University of British Columbia Multiple Sclerosis Clinic and Neuro-Immunology Laboratory, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/s0317167100014177DOI Listing
May 2013

Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression.

Mult Scler 2013 Apr 7;19(5):577-84. Epub 2012 Sep 7.

Faculty of Medicine, University of British Columbia, Vancouver, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458512459684DOI Listing
April 2013

Multiple sclerosis and inflammatory bowel diseases: what we know and what we would need to know!

Mult Scler 2013 Mar 1;19(3):259-65. Epub 2012 Oct 1.

Multiple Sclerosis Clinic, University of British Columbia Hospital, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458512461393DOI Listing
March 2013

Insights into origins of Human T-cell Lymphotropic Virus Type 1 based on new strains from aboriginal people of Canada.

Infect Genet Evol 2012 Dec 13;12(8):1822-30. Epub 2012 Aug 13.

National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, MB, Canada R3E 3R2.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.meegid.2012.07.015DOI Listing
December 2012

Hospital admissions and MS: temporal trends and patient characteristics.

Am J Manag Care 2012 Nov;18(11):735-42

Faculty of Medicine-Neurology, University of British Columbia, Vancouver, Canada.

View Article

Download full-text PDF

Source
November 2012

Cancer risk in multiple sclerosis: findings from British Columbia, Canada.

Brain 2012 Oct 21;135(Pt 10):2973-9. Epub 2012 Jun 21.

Division of Neurology, Faculty of Medicine, Multiple Sclerosis Program, University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
https://academic.oup.com/brain/article-lookup/doi/10.1093/br
Publisher Site
http://dx.doi.org/10.1093/brain/aws148DOI Listing
October 2012

Natural, innate improvements in multiple sclerosis disability.

Mult Scler 2012 Oct 26;18(10):1412-21. Epub 2012 Jun 26.

Faculty of Medicine, Division of Neurology, University of British Columbia, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458512439119DOI Listing
October 2012

Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.

JAMA 2012 Jul;308(3):247-56

Division of Neurology and Brain Research Centre, Department of Medicine and Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2012.7625DOI Listing
July 2012

Long-term persistence with the immunomodulatory drugs for multiple sclerosis: a retrospective database study.

Clin Ther 2012 Feb 31;34(2):341-50. Epub 2012 Jan 31.

Faculty of Medicine Neurology, University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinthera.2012.01.006DOI Listing
February 2012

When to initiate disease-modifying drugs for relapsing remitting multiple sclerosis in adults?

Mult Scler Int 2011 17;2011:724871. Epub 2011 May 17.

Multiple Sclerosis Clinic and Neuro-Immunology Laboratory, Department of Medicine, University of British Columbia, Room S-159, 2211 Wesbrook Mall, Vancouver, BC, Canada V6T 2H5.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2011/724871DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195775PMC
November 2011

Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada.

Neurology 2011 Apr;76(17):1526-8

Neuro-Immunology Laboratory, Department of Medicine, Division of Neurology, UBC Hospital, University of British Columbia, 2211 Wesbrook Mall, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0b013e318217e735DOI Listing
April 2011

Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.

J Interferon Cytokine Res 2011 Mar 12;31(3):337-44. Epub 2011 Jan 12.

1 Department of Microbiology and Molecular Genetics, Medical College of Wisconsin , Milwaukee, Wisconsin.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jir.2010.0038DOI Listing
March 2011

Pathological basis of diffusely abnormal white matter: insights from magnetic resonance imaging and histology.

Mult Scler 2011 Feb 21;17(2):144-50. Epub 2010 Oct 21.

Pathology & Laboratory Medicine, University of British Columbia, Vancouver, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458510384008DOI Listing
February 2011

CCSVI: hope, hype or snake oil?

Can J Neurol Sci 2010 Nov;37(6):716

View Article

Download full-text PDF

Source
November 2010

Evidence for a two-stage disability progression in multiple sclerosis.

Brain 2010 Jul 27;133(Pt 7):1900-13. Epub 2010 Apr 27.

Service d'épidémiologie et santé publique, Centre Hospitalier Universitaire, Rennes, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/brain/awq076DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2892936PMC
July 2010

Where are we going with drugs to treat MS? Will cost continue to increase?

Can J Neurol Sci 2010 May;37(3):305-8

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/s0317167100010167DOI Listing
May 2010

Adult celiac disease with acetylcholine receptor antibody positive myasthenia gravis.

World J Gastroenterol 2009 Oct;15(38):4741-4

Department of Medicine (Gastroenterology and Neurology), University of British Columbia, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2761549PMC
http://dx.doi.org/10.3748/wjg.15.4741DOI Listing
October 2009

Terbutaline in myasthenia gravis: a pilot study.

J Neurol Sci 2009 Feb 26;277(1-2):150-4. Epub 2008 Oct 26.

Department of Neurology, and the Brain Research Institute, The University of Chicago, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2008.09.033DOI Listing
February 2009

The implications of immunogenicity for protein-based multiple sclerosis therapies.

J Neurol Sci 2008 Dec 25;275(1-2):7-17. Epub 2008 Sep 25.

Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, 710 North Lake Shore Drive, Abbott Hall 1121, Chicago IL 60611, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2008.08.003DOI Listing
December 2008

A biosensor-based characterization of the affinity maturation of the immune response against interferon-beta and correlations with neutralizing antibodies in treated multiple sclerosis patients.

J Interferon Cytokine Res 2008 Dec;28(12):713-23

NeuroImmunology Labs, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jir.2008.0144DOI Listing
December 2008

Escalating immunotherapy of multiple sclerosis.

Ther Adv Neurol Disord 2008 Nov;1(3):181-92

Director, Multiple Sclerosis Program Division of Neurology, University of British Columbia, Vancouver, Canada

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1756285608098359DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002550PMC
November 2008

Bilirubin possesses powerful immunomodulatory activity and suppresses experimental autoimmune encephalomyelitis.

J Immunol 2008 Aug;181(3):1887-97

Brain Research Center, University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.181.3.1887DOI Listing
August 2008

Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients.

J Immunol Methods 2008 Jul 1;336(2):113-8. Epub 2008 May 1.

Neuro-Immunology Laboratory, University of British Columbia, Vancouver, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jim.2008.03.014DOI Listing
July 2008

HTLV-1 infection and the viral etiology of multiple sclerosis.

Authors:
Joël Oger

J Neurol Sci 2007 Nov 6;262(1-2):100-4. Epub 2007 Aug 6.

Multiple Sclerosis Clinic and Brain Research Centre, The University of British Columbia, Division of Neurology, Department of Medicine, Room S-159, UBC Hospital, Vancouver BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2007.06.045DOI Listing
November 2007

The IgG subclass-specificities of anti-IFNbeta antibodies change with time and differ between the IFNbeta products in relapsing remitting multiple sclerosis patients.

J Neuroimmunol 2007 Oct 7;190(1-2):146-50. Epub 2007 Sep 7.

Neuro-Immunology Laboratory, Department of Medicine, University of British Columbia, 2211 Wesbrook Mall, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S016557280700265
Publisher Site
http://dx.doi.org/10.1016/j.jneuroim.2007.07.022DOI Listing
October 2007

Immunosuppression: promises and failures.

Authors:
Joël Oger

J Neurol Sci 2007 Aug 23;259(1-2):74-8. Epub 2007 Mar 23.

Division of Neurology, Department of Medicine, Multiple Sclerosis Clinic and Brain Research Centre, The University of British Columbia, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2006.05.073DOI Listing
August 2007

Neutralizing antibodies to interferon beta in multiple sclerosis: analytical evaluation for validation of a cytopathic effect assay.

Clin Chim Acta 2007 Feb 30;377(1-2):185-91. Epub 2006 Sep 30.

Laboratoire d'Hormonologie-Marqueurs, CHU Ponchaillou, 35033 Rennes, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cca.2006.09.021DOI Listing
February 2007

During 3 years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4.

J Neuroimmunol 2006 Aug 12;177(1-2):161-6. Epub 2006 Jun 12.

University of British Columbia, Department of Medicine, Room S-159, 2211 Wesbrook Mall, Vancouver, BC, Canada V6T 2B5.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jneuroim.2006.04.024DOI Listing
August 2006

Should neutralizing antibodies be monitored during interferon-beta treatment for multiple sclerosis?

Nat Clin Pract Neurol 2006 Feb;2(2):76-7

Division of Neurology, the Department of Pathology, University of British Columbia, Vancouver, Canada.

View Article

Download full-text PDF

Source
http://www.nature.com/doifinder/10.1038/ncpneuro0098
Publisher Site
http://dx.doi.org/10.1038/ncpneuro0098DOI Listing
February 2006

Reappraisal of Lhermitte's sign in multiple sclerosis.

Mult Scler 2005 Aug;11(4):398-402

Multiple Sclerosis Clinic, University of British Columbia, Vancouver, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1191/1352458505ms1177oaDOI Listing
August 2005

Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis.

J Neurol 2004 Nov;251(11):1297-303

Department of Medicine (Neurology) rm S159, Vancouver Hospital and Health Sciences Centre, University of British Columbia, 2211 Wesbrook Mall, Vancouver, BC, V6T 2B5, Canada.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00415-004-0619-5
Publisher Site
http://dx.doi.org/10.1007/s00415-004-0619-5DOI Listing
November 2004

Elevated aminotransferases during treatment with interferon-beta for multiple sclerosis: actions and outcomes.

Mult Scler 2004 Jun;10(3):298-301

University of British Columbia, Department of Medicine, Division of Neurology, Vancouver Hospital and Health Sciences Center, UBC Site, S159-2211 Wesbrook Mall, Vancouver, BC, Canada V6T 2B5.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1191/1352458504ms1007oaDOI Listing
June 2004

Liver injury associated with the beta-interferons for MS: a comparison between the three products.

Neurology 2004 Feb;62(4):628-31

Department of Medicine, Division of Neurology, Vancouver Hospital & Health Sciences Center, University of British Columbia, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/wnl.62.4.628DOI Listing
February 2004

The measurement of antibodies binding to IFNbeta in MS patients treated with IFNbeta.

Neurology 2003 Nov;61(9 Suppl 5):S18-20

Department of Neurology and Neurosciences, UMDNJ-New Jersey Medical School, Newark, NJ 07103, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/01.wnl.0000092359.93813.92DOI Listing
November 2003

Evolution of focal and diffuse magnetisation transfer abnormalities in multiple sclerosis.

J Neurol 2003 Aug;250(8):924-31

Dept. of Physics & Astronomy, University of British Columbia, 2211 Wesbrook Mall, Vancouver BC, V6T 2B5, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00415-003-1115-zDOI Listing
August 2003

Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.

Neurology 2003 Aug;61(4):551-4

Division of Neurology, Department of Medicine, University of British Columbia, Vancouver Hospital and Health Sciences Center, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/01.wnl.0000078885.05053.7dDOI Listing
August 2003

Interferons in relapsing remitting multiple sclerosis.

Lancet 2003 May;361(9371):1822-3; author reply 1823-4

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(03)13419-8DOI Listing
May 2003

MRI contributes to the differentiation between MS and HTLV-I associated myelopathy in British Columbian coastal natives.

Can J Neurol Sci 2003 Feb;30(1):41-8

Multiple Sclerosis Clinic, Department of Medicine, Faculty of Medicine, University of British Columbia and UBC Hospital, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/s0317167100002420DOI Listing
February 2003

In myasthenia gravis, clinical and immunological improvement post-thymectomy segregate with results of in vitro antibody secretion by immunocytes.

J Neurol Sci 2002 Oct;202(1-2):77-83

Brain Research Centre and Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0022-510x(02)00226-5DOI Listing
October 2002